Pulmatrix, Inc. Common Stock
PULMStock
$1.61−74.51%52W
Market Cap$5.88M
P/E—
Div yield—
Beta1.98
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-41.20%
Price vs S&P 500 (4W)4.77%
VGM Score45.91
Market Capitalization$5.88M
Analyst Recommendations
Dec 2024
Jan 2025
Feb 2025
Mar 2025
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PULMPulmatrix, Inc. Common Stock | A | F | D | $1.61 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Pulmatrix is a biopharmaceutical company developing inhaled therapies for migraine and respiratory diseases using its proprietary iSPERSE dry powder delivery platform. Its clinical pipeline includes PUR3100 for acute migraine, PUR1800 for COPD exacerbations, and PUR1900 for aspergillosis in asthma and cystic fibrosis patients, targeting significant unmet medical needs.